Literature DB >> 31080940

First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia.

Yazan Numan1, Mansour Alfayez1, Abhishek Maiti2, Yesid Alvarado1, Elias J Jabbour1, Alessandra Ferrajoli1, Sergej N Konoplev3, Hagop M Kantarjian1, Prithviraj Bose1.   

Abstract

Entities:  

Year:  2018        PMID： 31080940      PMCID： PMC6508880          DOI： 10.1200/PO.18.00127

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  10 in total

1.  The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL.

Authors:  Alessandra Di Grande; Sofie Peirs; Paul D Donovan; Maaike Van Trimpont; Julie Morscio; Beatrice Lintermans; Lindy Reunes; Niels Vandamme; Steven Goossens; Hien Anh Nguyen; Arnon Lavie; Richard B Lock; Jochen H M Prehn; Pieter Van Vlierberghe; Triona Ní Chonghaile
Journal:  Blood Adv       Date:  2021-04-13

Review 2.  Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage.

Authors:  Lindsey E Montefiori; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2021-10-23       Impact factor: 3.020

3.  The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China.

Authors:  Jinyan Xiao; Zihong Cai; Hao Wang; Xuekai Li; Biqi Zhou; Yujie Liu; Ying Wang; Peipei Xu; Li Wang; Depei Wu; Liping Dou; Hongsheng Zhou; Yang Xu
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

4.  In Silico Integration of Transcriptome and Interactome Predicts an ETP-ALL-Specific Transcriptional Footprint that Decodes its Developmental Propensity.

Authors:  Soumyadeep Mukherjee; Arpita Kar; Paramita Paul; Souvik Dey; Avik Biswas; Subhasis Barik
Journal:  Front Cell Dev Biol       Date:  2022-05-13

Review 5.  The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.

Authors:  Marta Weronika Lato; Anna Przysucha; Sylwia Grosman; Joanna Zawitkowska; Monika Lejman
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

6.  Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.

Authors:  Vinod A Pullarkat; Norman J Lacayo; Elias Jabbour; Jeffrey E Rubnitz; Ashish Bajel; Theodore W Laetsch; Jessica Leonard; Susan I Colace; Seong Lin Khaw; Shaun A Fleming; Ryan J Mattison; Robin Norris; Joseph T Opferman; Kathryn G Roberts; Yaqi Zhao; Chunxu Qu; Mohamed Badawi; Michelle Schmidt; Bo Tong; John C Pesko; Yan Sun; Jeremy A Ross; Deeksha Vishwamitra; Lindsey Rosenwinkel; Su Young Kim; Amanda Jacobson; Charles G Mullighan; Thomas B Alexander; Wendy Stock
Journal:  Cancer Discov       Date:  2021-02-16       Impact factor: 38.272

7.  Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant.

Authors:  Ashley McEwan; Omali Pitiyarachchi; Nicholas Viiala
Journal:  Hemasphere       Date:  2020-06-08

Review 8.  Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts.

Authors:  Omar Castaneda Puglianini; Nikolaos Papadantonakis
Journal:  Ther Adv Hematol       Date:  2020-07-16

9.  Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations.

Authors:  Jonathan Wong; Meaghan Wall; Gregory Philip Corboy; Nadine Taubenheim; Gareth Peter Gregory; Stephen Opat; Jake Shortt
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-08-25

10.  Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Roberta La Starza; Benedetta Cambò; Antonio Pierini; Beat Bornhauser; Anna Montanaro; Jean-Pierre Bourquin; Cristina Mecucci; Giovanni Roti
Journal:  JCO Precis Oncol       Date:  2019-09-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.